Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 31;12:5183. doi: 10.1038/s41467-021-25405-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Kaplan–Meier (KM) estimates showing a overall survival (OS) for all PBL patients with available follow-up (FU) (n = 49) and b OS according to IPI group (IPI low: 0–1, IPI intermediate: 2–3, IPI high: 4–5). Lymphoma-specific survival (LSS) shown for PBL patients treated with CHOP-like chemotherapy depending on c EBV infection status of lymphoma (neg negative, pos positive), on d mutational status of TP53, and e NRAS (wt wildtype, mut mutated). Corresponding p values of two-sided log rank tests are shown, for multiple hypothesis testing over preselected conditions see Supplementary Data 9. f Hazard ratios by Cox regression and corresponding p_Cox values describing the impact of significant mutations, SCNAs (with q_M2CV/G2.0 < 0.1) or clinical metadata on LSS for PBL patients treated with CHOP-like chemotherapy. The size of the circle for parameters with p value <0.1 is proportional to the number of affected patients. Earlier findings confirmed by this unbiased exploratory analysis are highlighted in orange. No significant hypotheses with FDR q < 0.1 were found.